Roland W. Herzog mainly focuses on Immunology, Genetic enhancement, Factor IX, Immune system and Transgene. Antibody is the focus of his Immunology research. His biological study spans a wide range of topics, including Vector, Internal medicine, Partial thromboplastin time and Null allele.
While the research belongs to areas of Factor IX, Roland W. Herzog spends his time largely on the problem of Intramuscular injection, intersecting his research to questions surrounding Adenoviridae. His study in the field of Immune tolerance, Innate immune system and T cell also crosses realms of Cold storage. The concepts of his Transgene study are interwoven with issues in Molecular biology, Gene product and Virology.
His primary scientific interests are in Immunology, Immune system, Genetic enhancement, Factor IX and Immune tolerance. His Immunology research includes themes of Genetic transfer and Adeno-associated virus. His research in Immune system intersects with topics in Cytotoxic T cell, Bioinformatics, Antigen and Cell biology.
His Genetic enhancement research integrates issues from Transgene, Virology, Vector, Coagulation and Viral vector. The various areas that Roland W. Herzog examines in his Transgene study include Molecular biology, Gene expression and Transduction. His Factor IX study combines topics in areas such as Mutation, Intramuscular injection, Gene delivery and Skeletal muscle.
His primary areas of study are Genetic enhancement, Immune system, Bioinformatics, Cell biology and Coagulation. His Genetic enhancement research is multidisciplinary, incorporating perspectives in Vector, Internal medicine, Oncology and Chimera. His Immune system research entails a greater understanding of Immunology.
His study on Bioinformatics also encompasses disciplines like
His main research concerns Genetic enhancement, Immune system, Bioinformatics, Coagulation and Cell biology. His Genetic enhancement research is multidisciplinary, incorporating elements of Genetically modified organism, Hepatitis C virus, Hepatocyte, Liver disease and In vivo. His Immune system study is concerned with the larger field of Immunology.
His research integrates issues of Protein replacement therapy, Clotting factor, Anticoagulant and Small interfering RNA in his study of Bioinformatics. He combines subjects such as Dendritic cell, CD8, Cytotoxic T cell, Antigen presentation and Innate immune system with his study of Cell biology. Roland W. Herzog interconnects Vector, Hemophilias, Cell therapy and Adoptive cell transfer in the investigation of issues within Viral vector.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
Mark A. Kay;Catherine S. Manno;Catherine S. Manno;Margaret V. Ragni;Peter J. Larson;Peter J. Larson.
Nature Genetics (2000)
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
Catherine S. Manno;Amy J. Chew;Sylvia Hutchison;Peter J. Larson.
LONG-TERM CORRECTION OF CANINE HEMOPHILIA B BY GENE TRANSFER OF BLOOD COAGULATION FACTOR IX MEDIATED BY ADENO-ASSOCIATED VIRAL VECTOR
Roland W. Herzog;Edmund Y. Yang;Linda B. Couto;J. Nathan Hagstrom.
Nature Medicine (1999)
STABLE GENE TRANSFER AND EXPRESSION OF HUMAN BLOOD COAGULATION FACTOR IX AFTER INTRAMUSCULAR INJECTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS
R W Herzog;J N Hagstrom;S H Kung;S J Tai.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Progress and prospects: immune responses to viral vectors
Sushrusha Nayak;Roland W. Herzog.
Gene Therapy (2010)
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.
Li Zhong;Baozheng Li;Cathryn S. Mah;Lakshmanan Govindasamy.
Proceedings of the National Academy of Sciences of the United States of America (2008)
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Federico Mingozzi;Yi-Lin Liu;Eric Dobrzynski;Antje Kaufhold.
Journal of Clinical Investigation (2003)
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Jane D. Mount;Roland W. Herzog;D. Michael Tillson;Susan A. Goodman.
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Glenn P. Niemeyer;Glenn P. Niemeyer;Roland W. Herzog;Jane Mount;Valder R. Arruda.
Immune Responses to Viral Gene Therapy Vectors.
Jamie L. Shirley;Ype P. de Jong;Cox Terhorst;Roland W. Herzog.
Molecular Therapy (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: